楚天科技股份有限公司 子公司管理制度 第一章 总 则 第一条 为优化楚天科技股份有限公司（简称"公司"）及其控股、全资子 公司（以下统称"子公司"）的管理机制，确保子公司规范运营，保障股东合法 权益，依据《中华人民共和国公司法》、《中华人民共和国证券法》、《深圳证 券交易所创业板股票上市规则》（以下简称"《上市规则》"）、《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（以下简称 "《规范运作指引》"）以及《楚天科技股份有限公司章程》（以下简称"《公 司章程》"）等相关法律法规，并结合公司实际情况，特制定本制度。 第二条 本制度部分用语含义为： （一）"子公司"，是指公司根据总体战略规划、产业结构调整及业务发展 需要而依法设立的，具有独立法人资格，公司依据章程或协议有权决定其财务和 经营决策，据以从该企业的经营活动中获取利益的子公司。其设立形式包括： 1、全资子公司； 2、公司与其他公司或自然人共同出资设立的，公司控股 50%以上（不含 50%） 或派出董事占其董事会决大多数席位（控制其董事会）的控股子公司或通过协议、 其他安排能实现控制的子公司。 （二）"子公司管理"，是指公司作 ...

楚天科技股份有限公司 2024年度独立董事述职报告 （张早平） 各位股东及股东代表： 本人张早平，担任楚天科技股份有限公司（以下简称"楚天科技"或"公 司"）第五届董事会的独立董事。在履职期间，我严格遵循《中华人民共和国公 司法》、《中华人民共和国证券法》、《上市公司独立董事管理办法》、《深圳 证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等相关 法律、法规及规范性文件，以及《公司章程》、《独立董事工作细则》等内部规 定，秉持诚实、勤勉、独立的原则，认真履行职责。我积极参与各项会议，审慎 审议董事会各项议案，并对公司重大事项提出独立见解，充分发挥了独立董事及 专业委员会的职能，切实维护了全体股东，尤其是中小股东的合法权益。 现将本人2024年度履职情况总结如下： 一、基本情况 本人张早平，1965年12月出生，中国国籍，无境外永久居留权，博士，研究 员职称（2005年9月）。系湖南省十二届人大法制委委员，湖南省立法研究会副 会长，长沙市人民政府首批法制专家库专家，湖南省地方金融监督管理立法建设 主要参与者之一。曾在长沙市人事局军培中心、湖南华大电力科技开发公司任职。 现任长沙大地经济发展研究 ...

第一章 总 则 第一条 为规范楚天科技股份有限公司（以下简称"公司"）董事、 高级管理人员所持本公司股份及其变动的管理，进一步明确管理程序，确 保信息披露工作合规，根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自 律监管指引第 2 号—创业板上市公司规范运作》等相关法律、法规、规范 性文件，以及《楚天科技股份有限公司章程》（以下简称"《公司章程》"） 的明确规定，特制定本制度。 楚天科技股份有限公司 董事、高级管理人员持股及变动管理制度 第二条 本制度适用于公司董事和高级管理人员所持本公司股份及其 变动的管理。 第三条 公司董事和高级管理人员所持股份，是指登记在其名下的所 有本公司股份及其衍生产品（包括但不限于可转换债券、股权激励计划所 发行的股票期权及股票增值权）等；董事和高级管理人员从事融资融券交 易的，还包括记载在其他信用账户内的本公司股份及其衍生产品，同时亦 包括任何股权激励计划所发行的股票期权及股票增值权。 第四条 公司董事和高级管理人员在买卖本公司股票及其衍生品种前， 应 ...

楚天科技股份有限公司 独立董事工作制度 第一章 总 则 1 会计专业人士应当具备丰富的会计专业知识和经验，并至少符合下列条件之一： 第一条 为进一步完善楚天科技股份有限公司（以下简称"公司"）的法人治 理结构，加强对董事会和经理层的约束与监督，提升公司决策的科学性与民主性， 维护公司及全体股东的利益，根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》等相关法律、法规，以及《楚天科技股份有 限公司章程》（以下简称"《公司章程》"或"公司章程"）的规定，遵循《深圳 证券交易所创业板股票上市规则（2024年修订）》（以下简称"《股票上市规 则》"）、《上市公司独立董事管理办法》（以下简称"《独董管理办法》"）、 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作 （2023年12月修订）》的相关要求，结合公司实际情况，特制定本制度。 第二条 公司独立董事是指不在公司担任除董事外的其他职务，并与公司及其 主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能妨碍其进行独立 客观判断关系的董事。 第三条 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人、 ...

Financial Performance - The company reported a decline in performance, with specific reasons detailed in the "Analysis of Four Main Businesses" section of the report[5]. - The company's operating revenue for 2024 was ¥5,829,800,576.60, a decrease of 14.94% compared to ¥6,853,359,543.02 in 2023[21]. - The net profit attributable to shareholders for 2024 was ¥317,075,752.08, representing a significant decline of 242.76% from ¥567,448,293.44 in 2023[21]. - The net cash flow from operating activities decreased by 40.19% to ¥122,341,832.53 in 2024, down from ¥204,544,610.05 in 2023[21]. - The company's basic earnings per share for 2024 was -¥0.7668, a decrease of 240.29% from ¥0.5466 in 2023[21]. - The company reported a total of ¥40,433,908.96 in non-recurring gains and losses for 2024, compared to ¥7,604,237.83 in 2023[28]. - The company experienced a negative net profit for all four quarters of 2024, with the fourth quarter showing a net loss of ¥265,404,923.97[24]. - The net profit attributable to the company, after deducting non-recurring gains and losses, was a loss of ¥493,091,896.83, a decline of 259.33% compared to the previous year[61]. - The comprehensive gross profit margin for the main business was 25.87%, down 5.57% year-on-year[61]. Strategic Outlook - The company plans to enhance its future development strategies as outlined in the "Outlook for Future Development" section[5]. - The company aims to become a leading global pharmaceutical equipment provider by around 2030, focusing on a comprehensive solution for pharmaceutical production 4.0[45]. - The company is enhancing its brand influence in international markets, with a steady increase in overseas market share[49]. - The company aims to leverage its technological advantages and international strategies to enhance competitiveness in the mid-to-high-end market[39]. - The company plans to further expand its international market presence by segmenting global markets into five major regions, improving local responsiveness[69]. Market Position and Industry Trends - The company is positioned as a leading enterprise in the pharmaceutical equipment industry, focusing on providing specialized and intelligent solutions[31]. - The global pharmaceutical equipment market is projected to exceed $50 billion in 2024 and $80 billion by 2030, with a CAGR of approximately 6-8%[32]. - China's pharmaceutical manufacturing market is expected to reach $191.7 billion in 2024, with a CAGR of about 7.5% from 2024 to 2032[37]. - The demand for personalized, small-batch, and multi-variety production is increasing, driving a shift towards modular and flexible equipment[34]. - The company is benefiting from the upgrade of the pharmaceutical industry and is transitioning towards high-end manufacturing, enhancing its international competitiveness[31]. Product Development and Innovation - The company has developed a digital water technology product chain, providing lifecycle services for pharmaceutical water, water treatment, wastewater treatment, and resource utilization, while also expanding applications to new energy, electronic semiconductors, and fine chemicals[50]. - The company has expanded its product offerings to include a comprehensive skincare and daily chemical solution, exemplified by the successful establishment of a smart beauty factory for Shangmei Co., integrating industrial automation, intelligent control, and information management[50]. - The company has successfully developed a series of specialized robots for clean and sterile environments, addressing the market's demand for high-precision and flexible production[55]. - The company has introduced advanced processing techniques for various materials, improving product durability and market competitiveness[51]. - The company has launched a new sterilization logistics system targeting vials, with a production speed of 3-4 packages per minute[90]. Financial Management and Investments - The company reported a fair value change of ¥3,903,335 in financial assets, with a total of ¥630,775,465 at the end of the period[104]. - The company issued 10 million convertible bonds with a total fundraising amount of ¥100,000,000, netting ¥98,681,460 after deducting issuance costs[112]. - The company has ongoing significant non-equity investments, but specific details were not disclosed[107]. - The company has committed to various investment projects with a total investment amount of RMB 98.6 million, with a progress rate of 98.2%[114]. - The company plans to use RMB 154.3252 million to replace self-raised funds that were previously invested in fundraising projects[115]. Governance and Compliance - The company adheres to strict governance practices, ensuring compliance with laws and regulations, and enhancing risk prevention capabilities[135]. - The board of directors operates in accordance with legal requirements, with a focus on diligent performance of duties and responsibilities[138]. - The company has implemented a transparent performance evaluation and incentive mechanism for its directors and senior management[140]. - The company ensures timely and accurate information disclosure, adhering to relevant regulations and providing equal access to all investors[143]. - The internal control audit report issued a standard unqualified opinion, confirming the effectiveness of the financial reporting internal controls[200]. Human Resources and Employee Management - The total number of employees at the end of the reporting period was 7,005, including 4,012 at the parent company and 2,993 at major subsidiaries[184]. - The company has implemented a performance-oriented salary system, linking salary increases directly to performance assessments[186]. - The company has established a comprehensive talent development system, including training plans for new employees and ongoing professional development for existing staff[187]. - The company has reduced its R&D personnel by 29.67% from 2,720 in 2023 to 1,913 in 2024[93]. - The company has a total of 912.9 million shares of restricted stock that will be canceled due to performance assessment failures, affecting 559 incentive recipients[192].

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,083,171,677.45, a decrease of 22.19% compared to the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥8,556,904.43, an improvement of 59.00% from a loss of ¥20,871,739.14 in the previous year[4]. - Basic and diluted earnings per share were both -¥0.0145, showing a 59.04% improvement from -¥0.0354 in the previous year[4]. - The company's net profit margin was impacted by a significant increase in financial expenses, which rose to ¥22,886,756.40 from ¥10,384,913.00, reflecting a 120% increase[20]. - The net profit for the current period is -13,440,239.56, an improvement from -20,716,801.32 in the previous period, representing a decrease in net loss of approximately 35%[21]. - The total comprehensive income for the current period is 29,363,025.88, compared to -50,418,878.54 in the previous period, indicating a significant recovery[21]. - The total operating profit for the current period is -24,633,247.88, an improvement from -26,895,103.40 in the previous period, showing a reduction in operating losses[21]. Cash Flow - The net cash flow from operating activities improved by 67.85%, amounting to a net outflow of ¥147,730,837.30, compared to a net outflow of ¥459,497,946.67 in the same period last year[4]. - Cash flow from operating activities shows a net outflow of -147,730,837.30, an improvement from -459,497,946.67 in the previous period[23]. - Cash flow from investing activities has a net outflow of -119,669,546.19, compared to -868,984,903.03 in the previous period, indicating reduced investment losses[23]. - Cash flow from financing activities shows a net inflow of 109,815,057.03, a decrease from 1,102,167,793.19 in the previous period, reflecting a reduction in financing activities[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥13,204,719,138.23, a decrease of 0.80% from the end of the previous year[4]. - Current liabilities totaled ¥7,182,337,198.32, down from ¥7,347,852,543.54, indicating a reduction of approximately 2.3%[19]. - The company's cash and cash equivalents decreased to ¥1,149,546,287.64 from ¥1,278,390,795.81, a decline of 10.1%[18]. - The cash and cash equivalents at the end of the period amount to 810,399,084.13, compared to 279,193,839.84 at the end of the previous period, showing an increase in liquidity[24]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 26,863[12]. - The largest shareholder, Changsha Chutian Investment Group, holds 38.07% of shares, totaling 224,706,614 shares[12]. - Hunan Caixin Jingxin Investment Partnership holds 2.68% of shares, totaling 15,816,000 shares[12]. - Liu Yan, an individual shareholder, holds 1.99% of shares, totaling 11,722,250 shares[12]. - The top 10 shareholders account for a significant portion of the company's equity, with the largest shareholder alone holding over 38%[12]. - The company has no preferred shareholders as indicated in the report[14]. - There are no changes in the number of restricted shares for key executives during the reporting period[15]. - The total number of restricted shares at the end of the period is 14,118,283 shares[15]. - The report indicates that key executives have locked shares that can be released gradually over their tenure[15]. - The company has not engaged in any share lending or borrowing activities during the reporting period[12]. Cost Management - Research and development expenses decreased by 34.14%, amounting to a reduction of ¥49,391,500 compared to the previous year[9]. - The company implemented cost reduction and efficiency enhancement measures, resulting in a 16.86% decrease in period expenses compared to the previous year[8]. Investment and Financing - Investment income increased by 424.89%, amounting to an increase of ¥1,430,200 compared to the previous year due to higher returns from bank wealth management products[9]. - The company reported a significant decrease in financing cash flow, down 90.04% to a net outflow of ¥99,235,270, primarily due to the absence of convertible bond issuance in the current period[10]. Revenue and Sales - The report indicates that sales revenue from goods and services was 1,404,767,950.05, down from 1,743,978,201.95 in the previous period, indicating a decline of approximately 19%[23]. - Total operating revenue for the current period was ¥1,083,171,677.45, a decrease of 22.2% compared to ¥1,392,029,678.89 in the previous period[20]. - Total operating costs amounted to ¥1,123,822,892.53, down 22.1% from ¥1,443,898,305.35 in the previous period[20]. Project Updates - The company has extended the timeline for the "Medical Equipment and Materials Technology Research Center Project" to March 2026, reflecting a cautious approach to current industry conditions[17]. - The board decided not to adjust the conversion price of the "Chutian Convertible Bonds" downward, maintaining the current terms for the next three months[16].

董秘： 您好！为保持2024年度报告与2025年一季度报告同步披露，故向深交所申请对年报披露时间进 行了调整，具体业绩情况届时请查阅相关报告。谢谢！ 当日关注点 交易信息汇总：4月24日主力资金净流出36.61万元，散户资金净流出63.22万元，而游资资金净流 入99.83万元。 交易信息汇总 董秘最新回复 投资者： 董秘您好，公司的产品对美国加征关税有没有影响，占比多少，今后是否加强欧洲布局 董秘： 您好！公司产品目前出口美国占总收入比非常小。公司将持续加大欧洲市场的拓展，进一步提 升在欧洲市场的占有率。以头部制药企业和高价值客户为主，对标国际头部制药装备同行，进一步提升 国际销售业务的利润水平。持续构建楚天科技在国际上的品牌影响力，持续深化国际销售及服务的本土 化策略，打造以高性价比、高效服务的品牌形象。谢谢！ 投资者： 贵公司年报怎么调整到29号了，是因为业绩太差了吗 截至2025年4月24日收盘，楚天科技(300358)报收于6.81元，下跌0.87%，换手率1.01%，成交量5.83万 手，成交额3993.21万元。 4月24日，楚天科技的资金流向情况如下：主力资金净流出36.61万元；游资资金净流 ...

4月2日，楚天科技今日收盘7.74元，上涨4.74%，最新市净率1.02，创14天以来新低，总市值45.69亿 元。 截至2024年三季报，共有32家机构持仓楚天科技，其中基金32家，合计持股数647.66万股，持股市值 0.44亿元。 楚天科技股份有限公司主营业务为制药装备的研发、设计、生产、销售和服务。主要产品为无菌制剂解 决方案及单机、检测包装解决方案及单机、生物工程解决方案及单机、固体制剂解决方案及单机、制药 用水装备及工程系统集成、EPC工程设计服务。公司已发展成为国内制药装备行业领军企业之一，同时 也成为了全球医药装备行业的知名企业之一。 最新一期业绩显示，2024年三季报，公司实现营业收入41.71亿元，同比-18.75%；净利润-187253063.9 元，同比-165.18%，销售毛利率25.94%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13楚天科技-29.0214.411.0245.69亿行业平均 46.8850.714.88109.12亿行业中值33.6731.142.5548.71亿1硕世生物-1962.70-1962.701.2340.55亿2诺唯 赞-584.37 ...

Summary of Key Points Core Viewpoint The announcement details the conversion of convertible bonds into shares of Chutian Technology Co., Ltd., highlighting the bond issuance, conversion status, and changes in the company's total share capital. Group 1: Convertible Bond Issuance - The company issued convertible bonds with a total face value of RMB 100 million, net proceeds amounting to RMB 98.68 million [1] - The bonds were approved by the China Securities Regulatory Commission and listed on the Shenzhen Stock Exchange on February 29, 2024 [2] Group 2: Conversion Details - The conversion period for the bonds is from August 6, 2024, to the maturity date, with an initial conversion price set at RMB 10.00 per share, later adjusted to RMB 8.00 per share [2][3] - As of the end of the first quarter of 2025, a total of 190 bonds were converted into 2,362 shares, leaving 9,999,810 bonds outstanding with a total face value of RMB 999.98 million [6] Group 3: Share Capital Changes - The total share capital increased from 590,304,611 shares to 590,304,736 shares due to the conversion, with a net increase of 125 shares [6] - The proportion of restricted shares held by executives remained stable, with a slight decrease in the number of locked shares due to executive turnover [6] Group 4: Other Information - Investors can refer to the full terms of the convertible bonds in the company's prospectus published on January 29, 2024 [7]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、楚天转债（债券代码：123240）转股期限为 2024 年 8 月 6 日至 2030 年 1 月 30 日，最新有效的转股价格为人民币 8.00 元/股。 2、2025 年第一季度，共有 10 张"楚天转债"完成转股（票面金额共计 1,000 元人民币），合计转成 125 股"楚天科技"股票（股票代码：300358）。 3、截至 2025 年第一季度末，楚天科技股份有限公司（以下简称"公司"） 剩余可转换公司债券（以下简称"可转债"）为 9,999,810 张，剩余票面总金额 为 99,998.10 万元人民币。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引第 15 号——可转换公司债券》的有关规定，公司现将 2025 年第一 季度可转债转股及公司总股本变化情况公告如下： 一、可转换公司债券发行基本情况 | 证券代码：300358 | 证券简称：楚天科技 | 公告编号：2025-014 | 号 | | --- | --- | --- | --- | | 债券代 ...